

Press Release

Revenue from operations up by 14% (1st Quarter FY 2026 Consolidated Results)

Mumbai, 28th July, 2025: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 1st quarter ended 30th June 2025.

Q1 FY 2026 performance highlights (compared to Q1 FY 2025):

- Revenue from operations at **Rs. 1,303 cr.** against Rs. 1,145 cr.; **up 14%.**
- EBITDA at **Rs. 351 cr.** against Rs. 330 cr.; up 6%; **EBITDA at 27%.**
- Profit after tax at **Rs. 255 cr.** against Rs. 246 cr.; up 4%; **PAT at 20%.**
- The mark-to-market forex loss stood at Rs. 25 cr. Excluding this impact, EBITDA stood at Rs. 376 cr., reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%.
- Cashflow from operations (CFO) was Rs. 282 cr., EBITDA to CFO conversion of 80%.
- Free cashflow (FCF) was Rs. 209 cr., FCF to PAT conversion of 82%.
- ROCE stood at a healthy level of 33% and RONW at 26%.

Segment wise performance:

(Rs. cr.)

| Markets | Q1 | | Gwth% |
|---------------------------|----------------|----------------|------------|
| | FY 2025 | FY 2026 | |
| Branded Generics | | | |
| India | ₹ 353 | ₹ 409 | 16% |
| Asia | ₹ 277 | ₹ 304 | 10% |
| Africa | ₹ 230 | ₹ 228 | -1% |
| Sub-Total | ₹ 860 | ₹ 941 | 9% |
| US Generic | ₹ 228 | ₹ 310 | 36% |
| Africa Institution | ₹ 42 | ₹ 38 | -8% |
| Total | ₹ 1,130 | ₹ 1,289 | 14% |

As per **IQVIA MAT June 2025**, our India branded generic performance exceeded IPM growth by **29%**. The higher growth came from **Volumes increase**, which exceeded IPM by **73%** & **New launches**, which exceeded IPM by **46%**.

| Therapy | Growth % | |
|-----------------|-----------|------------|
| | IPM | Ajanta |
| Cardiology | 12% | 8% |
| Ophthalmology | 5% | 9% |
| Dermatology | 9% | 13% |
| Pain Management | 7% | 10% |
| Overall | 8% | 10% |

ANDA status as at the end of Q1 FY 2026 is as below:

| Particulars | Q1 FY 2026 |
|-------------------------------|------------|
| Filed | Nil |
| Approval received | 1 |
| Launched | 1 |
| Total ANDA's commercialized | 47 |
| Awaiting approval with US FDA | 21 |
| Tentative approval | 2 |

R&D expense:

(Rs. cr.)

| Particulars | FY 2025 | FY 2026 | % to Revenue |
|-------------|---------|---------|--------------|
| Q1 | ₹ 51 | ₹ 56 | 4% |

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the Last 3 financial years, company has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1600 hrs. IST (1830 hrs. SST/HKT, 1130 hrs. BST, 0630 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

| | |
|--|---|
| Date and Time | July 28, 2025 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1130 – 1230 hrs BST 0630 – 0730 hrs US ET |
| Dial-in Numbers | |
| Diamond pass link for faster access | Click here to register |
| Universal Access | Primary Access: (+91 22 6280 1542) (+91 22 7115 8372) |
| International Toll Free | USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 |

For convenience and faster connectivity to the conference, kindly follow the below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the '[conference Dial-in number](#)' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Safe Harbour Statement